VIP in experimental arthritis: inflammation in an animal model

Evidence level: Animal research: experimental autoimmune arthritis · Publication year: 2001
This overview discusses one original scientific publication on VIP. The source is indexed in PubMed, the literature database of the U.S. National Library of Medicine.
What was studied?
The researchers studied VIP in an experimental arthritis model and examined both inflammatory processes and the autoimmune component of the disease.
What did the researchers find?
The study reported a lower incidence and severity of arthritis, with less joint swelling and less damage to cartilage and bone in the model used.
What are the limitations?
Animal models only replicate some aspects of human rheumatoid arthritis. The publication does not prove the efficacy or safety of VIP as a treatment in humans.
Significance for research
Here, VIP was studied as a signaling peptide in a specific immune model, not as a general anti-inflammatory agent for every application.
Official source
Original publication via PubMed — PMID 11329057 · DOI: 10.1038/87887
Research Use Only. This literature summary does not contain treatment or usage advice. Research on a molecule is not evidence of the efficacy, safety, or purity of a Peptidera product. PubMed indexing is not product approval.
Related research products
View product specifications and available batch documentation. The studies discussed were not conducted using Peptidera products and do not prove the efficacy of our products. For laboratory research only; not for human or animal consumption.